Study on Bladder and Sexual Function Change After Simple Hysterectomy
Incidence and Pattern of Overactive Bladder Symptoms Occurring After Hysterectomy
1 other identifier
observational
300
1 country
1
Brief Summary
To evaluate the incidence and pattern of bladder symptoms and sexual function change occuring after simple hysterectomy and to analyze the influence of bladder symptoms and sexual function change on quality of life of patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedFirst Submitted
Initial submission to the registry
September 4, 2012
CompletedFirst Posted
Study publicly available on registry
September 12, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2017
CompletedMay 31, 2017
May 1, 2017
4.8 years
September 4, 2012
May 27, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of bladder symptoms
within 6 months after surgery
Secondary Outcomes (3)
Pattern change of bladder symptoms after surgery
Baseline and within 6 months after surgery
Sexual function change
Baseline and within 6 months after surgery
Quality of life
within 6 months aftr surgery
Study Arms (1)
Simple hysterectomy group
Patients will undergo simple hysterectomy due to benign uterine disease.
Eligibility Criteria
Patinets who undergo simple hysterectomy due to benign uterine disease at university hospital
You may qualify if:
- Patients who is planed to undergo simple hysterectomy due to benign uterine disease
- Uterine leiomyoma
- Uterine adenomyosis
- Endometrial hyperplasia
- Cervical intraepithelial neoplasia (including carcinoma in situ, FIGO stage IA1 cancer)
- Dysfunctional uterine bleeding
- Other benign uterine disease requiring hysterectomy
You may not qualify if:
- Patients who are taking medication for overactive bladder
- Patients who underwent incontinence surgery due to urinary incontinence
- Acute or chronic infectious disease of urinary tract
- Neurologic disease causing urinary abnormality
- Previous pelvic radiation therapy
- Patients who are undergoing incontinence surgery with hysterectomy
- Pregnant woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Asan Medical Centerlead
- Astellas Pharma Inccollaborator
Study Sites (1)
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, 138-736, South Korea
Study Officials
- PRINCIPAL INVESTIGATOR
Hee-Dong Chae, M.D., Ph.D.
Asan Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
September 4, 2012
First Posted
September 12, 2012
Study Start
September 1, 2012
Primary Completion
July 1, 2017
Study Completion
July 1, 2017
Last Updated
May 31, 2017
Record last verified: 2017-05